e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
Pulmonary hypertension: novel insights into the biology of the disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: CFIm25 links alternative polyadenylation to pulmonary hypertension
Harry Karmouty-Quintana (Houston, United States of America), Tingting Weng, Ning-Yuan Chen, Michael Blackburn, Eric Wagner, Harry Karmouty Quintana
Source:
International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Session:
Pulmonary hypertension: novel insights into the biology of the disease
Session type:
Thematic Poster Session
Number:
2428
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Harry Karmouty-Quintana (Houston, United States of America), Tingting Weng, Ning-Yuan Chen, Michael Blackburn, Eric Wagner, Harry Karmouty Quintana. LATE-BREAKING ABSTRACT: CFIm25 links alternative polyadenylation to pulmonary hypertension. Eur Respir J 2015; 46: Suppl. 59, 2428
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Systemic vascular function in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
LATE-BREAKING ABSTRACT: Evidence for a critical contribution of pericytes in pulmonary arterial hypertension pathogenesis
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016
LATE-BREAKING ABSTRACT: Peak oxygen consumption improves in inoperable, but not operable, chronic thromboembolic pulmonary hypertension after treatment with pulmonary arterial hypertension drugs
Source: Annual Congress 2013 –New physiologic boundaries
Year: 2013
Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary hypertension in COPD
Source: Eur Respir J 2008; 32: 1371-1385
Year: 2008
LATE-BREAKING ABSTRACT: The bromodomain-containing protein 4: the epigenetic origin of the oncogenic signature in pulmonary hypertension
Source: International Congress 2014 – New technologies and biomarkers in lung disease
Year: 2014
Left ventricular-arterial coupling and cardiac remodeling in patients with idiopathic arterial pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load
Year: 2015
Pulmonary hypertension in patients with COPD
Source: Eur Respir Mon 2012; 57: 138-147
Year: 2012
LATE-BREAKING ABSTRACT: TNFalpha mediates ectodomain shedding of BMPR-II: A potential role in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: basic science
Year: 2013
Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension
Source: International Congress 2016 – Pulmonary hypertension: the clinic I
Year: 2016
Evidence of renal and pulmonary endothelial dysfunction in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Pulmonary hypertension in chronic lung disease and hypoxia
Source: Eur Respir J, 53 (1) 1801914; 10.1183/13993003.01914-2018
Year: 2019
LATE-BREAKING ABSTRACT: The effect of volume overload on pulmonary hypertension in hemodialysis patients
Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH
Year: 2015
LATE-BREAKING ABSTRACT: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension
Source: International Congress 2014 – New technologies and biomarkers in lung disease
Year: 2014
The effect of chronic dosing of riociguat on acute hypoxic pulmonary vasoconstriction in respiratory disease
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Challenging cases in PH
Source: Eur Respir Rev 2008; 17: 19-23
Year: 2007
Cardiac remodeling and left ventricular-arterial coupling in patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
Source: Eur Respir Rev 2009; 19: 59-63
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept